Written question asked by Lord Mendelsohn (Labour) on Thursday, 12 May 2022, in the House of Lords. It was due for an answer on Thursday, 26 May 2022. It was answered by Lord Kamall (Conservative) on Wednesday, 25 May 2022 on behalf of the Department of Health and Social Care.

Tixagevimab/cilgavimab

Question: To ask Her Majesty's Government, further to the Written Answer by the Parliamentary Under-Secretary of State for the Department of Health and Social Care on 20 April (151279), what the in vitro data has shown about Evusheld’s efficacy against Omicron sub-lineage BA.2 VOC-22JAN-01.

Original answer: The UK Health Security Agency is continuing further testing on the treatment’s effectiveness against the Omicron variants, including BA.1 and BA.2. The timing of these results is dependent on identification of new variants of concern and technical scientific assays.

It has since been corrected.

Secondary information

Type: Written question
Reference: HL219
Session: 2022-23
Related items: Tixagevimab/cilgavimab
Wednesday, 20 April 2022
Written questions
House of Commons; Correction to Written Parliamentary Questions
Monday, 17 April 2023
Written statements
House of Commons; Correction to Written Parliamentary Questions
Monday, 17 April 2023
Written statements
House of Lords
Notes: Information corrected on 17 April at 731 c10-2WS
Subjects: Testing Tixagevimab/cilgavimab
Link: View this Written question on www.parliament.uk